25 Recruiting Studies Using Rilvegostomig
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Rilvegostomig
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
📍 Research Site — Baltimore, Maryland
Gastric Cancer
View Study & Checklist ➔Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
📍 Research Site — Birmingham, Alabama
Biliary Tract Cancer
View Study & Checklist ➔Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
📍 Research Site — Birmingham, Alabama
Hepatocellular Carcinoma
View Study & Checklist ➔A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
📍 Research Site — Tucson, Arizona
Non-small Cell Lung Cancer
View Study & Checklist ➔Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
📍 LSU Health Sciences Center - Shreveport — Shreveport, Louisiana
Solid Tumor
View Study & Checklist ➔A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
📍 Research Site — Birmingham, Alabama
Biliary Tract Cancer
View Study & Checklist ➔Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
📍 Research Site — Little Rock, Arkansas
Non-small Cell Lung Cancer
View Study & Checklist ➔Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
📍 Research Site — Mobile, Alabama
Gastric Cancer
View Study & Checklist ➔Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
📍 Research Site — Duarte, California
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
View Study & Checklist ➔I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
📍 University of Alabama at Birmingham — Birmingham, Alabama
Breast Neoplasms
View Study & Checklist ➔DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
📍 Research Site — Tucson, Arizona
Endometrial Cancer
View Study & Checklist ➔A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
📍 Research Site — Newark, Delaware
Gastroesophageal Adenocarcinoma
View Study & Checklist ➔Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
📍 Research Site — Phoenix, Arizona
Hepatocellular Carcinoma
View Study & Checklist ➔An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
📍 Research Site — Hot Springs, Arkansas
High-risk Muscle Invasive Urothelial Carcinoma
View Study & Checklist ➔Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
📍 Research Site — Los Angeles, California
Gastric Cancer
View Study & Checklist ➔A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
📍 Research Site — La Mesa, California
Carcinoma, Non-Small Cell Lung
View Study & Checklist ➔A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
📍 Research Site — Anchorage, Alaska
HER2-positive Gastric Cancer
View Study & Checklist ➔A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
📍 Research Site — Tucson, Arizona
Non-small Cell Lung Cancer
View Study & Checklist ➔Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
📍 Research Site — Anchorage, Alaska
Non-Small Cell Lung Cancer
View Study & Checklist ➔A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
📍 Research Site — Grand Rapids, Michigan
Melanoma
View Study & Checklist ➔Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
📍 Research Site — Scottsdale, Arizona
Biliary Tract Cancer
View Study & Checklist ➔A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
📍 Research Site — Phoenix, Arizona
Advanced or Metastatic Non-small Cell Lung Cancer
View Study & Checklist ➔Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
📍 Research Site — Los Angeles, California
Endometrial Cancer
View Study & Checklist ➔A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
📍 Research Site — Mobile, Alabama
Non-squamous Non-small Cell Lung Cancer
View Study & Checklist ➔A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
📍 Research Site — Santa Monica, California
Non-Small Cell Lung Cancer
View Study & Checklist ➔